Molecular and Cellular Studies Evaluating a Potent 2-cyanoindolizine Catechol Diether NNRTI Targeting Wildtype and Y181C Mutant HIV-1 Reverse Transcriptase

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2019 Jul 9

PMID 31281023

Citations 2

Authors

Tomoaki Sasaki

Zira T K Gannam

Shalley N Kudalkar

Kathleen M Frey

Won-Gil Lee

Krasimir A Spasov

William L Jorgensen

Karen S Anderson

Affiliations

Soon will be listed here.

Abstract

The development of efficacious NNRTIs for HIV/AIDS therapy is commonly met with the emergence of drug resistant strains, including the Y181C variant. Using a computationally-guided approach, we synthesized the catechol diether series of NNRTIs, which display sub-nanomolar potency in cellular assays. Among the most potent were a series of 2-cyanoindolizine substituted catechol diethers, including Compound 1. We present here a thorough evaluation of this compound, including biochemical, cellular, and structural studies. The compound demonstrates low nanomolar potency against both WT and Y181C HIV-1 RT in in vitro and cellular assays. Our crystal structures of both the wildtype and mutant forms of RT in complex with Compound 1 allow the interrogation of this compound's features that allow it to maintain strong efficacy against the drug resistant mutant. Among these are compensatory shifts in the NNRTI binding pocket, persistence of multiple hydrogen bonds, and van der Waals contacts throughout the binding site. Further, the fluorine at the C6 position of the indolizine moiety makes multiple favorable interactions with both RT forms. The present study highlights the indolizine-substituted catechol diether class of NNRTIs as promising therapeutic candidates possessing optimal pharmacological properties and significant potency against multiple RT variants.

Citing Articles

Virulence and Replicative Fitness of HIV-1 Transmitted/Founder (T/F) Viruses Harbouring Drug Resistance-Associated Mutation.

Sonawane A, Selvam D, Yue L, Nesakumar M, Vivekanandan S, Ashokkumar M Viruses. 2025; 16(12.

PMID: 39772167 PMC: 11680346. DOI: 10.3390/v16121854.

Exploring novel HIV-1 reverse transcriptase inhibitors with drug-resistant mutants: A double mutant surprise.

Hollander K, Chan A, Frey K, Hunker O, Ippolito J, Spasov K Protein Sci. 2023; 32(12):e4814.

PMID: 37861472 PMC: 10659932. DOI: 10.1002/pro.4814.

Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.

Vanangamudi M, Nair P, Engels S, Palaniappan S, Namasivayam V Adv Exp Med Biol. 2021; 1322:63-95.

PMID: 34258737 DOI: 10.1007/978-981-16-0267-2_3.

References

Reynolds C, de Koning C, Pelly S, van Otterlo W, Bode M . In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Chem Soc Rev. 2012; 41(13):4657-70. DOI: 10.1039/c2cs35058k. View

Pannecouque C, Daelemans D, De Clercq E . Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc. 2008; 3(3):427-34. DOI: 10.1038/nprot.2007.517. View

De Clercq E . Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers. 2006; 1(1):44-64. DOI: 10.1002/cbdv.200490012. View

Janssen P, Lewi P, Arnold E, Daeyaert F, De Jonge M, Heeres J . In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem. 2005; 48(6):1901-9. DOI: 10.1021/jm040840e. View

Lai M, Feng M, Falgueyret J, Tawa P, Witmer M, DiStefano D . In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014; 58(3):1652-63. PMC: 3957832. DOI: 10.1128/AAC.02403-13. View

Bollini M, Domaoal R, Thakur V, Gallardo-Macias R, Spasov K, Anderson K . Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem. 2011; 54(24):8582-91. PMC: 3258498. DOI: 10.1021/jm201134m. View

Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P . Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004; 351(3):229-40. DOI: 10.1056/NEJMoa041305. View

Kudalkar S, Beloor J, Chan A, Lee W, Jorgensen W, Kumar P . Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection. Mol Pharmacol. 2017; 91(4):383-391. PMC: 5363707. DOI: 10.1124/mol.116.107755. View

Lindberg J, Sigurdsson S, Lowgren S, Andersson H, Sahlberg C, Noreen R . Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem. 2002; 269(6):1670-7. DOI: 10.1046/j.1432-1327.2002.02811.x. View

10.

Weuts I, Van Dycke F, Voorspoels J, De Cort S, Stokbroekx S, Leemans R . Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J Pharm Sci. 2010; 100(1):260-74. DOI: 10.1002/jps.22242. View

11.

Tantillo C, Ding J, Nanni R, Boyer P, Hughes S, Pauwels R . Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994; 243(3):369-87. DOI: 10.1006/jmbi.1994.1665. View

12.

Xu H, Asahchop E, Oliveira M, Quashie P, Quan Y, Brenner B . Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol. 2011; 85(21):11300-8. PMC: 3194954. DOI: 10.1128/JVI.05584-11. View

13.

Cote B, Burch J, Asante-Appiah E, Bayly C, Bedard L, Blouin M . Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014; 24(3):917-22. DOI: 10.1016/j.bmcl.2013.12.070. View

14.

Bacheler L, Anton E, Kudish P, Baker D, Bunville J, Krakowski K . Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother. 2000; 44(9):2475-84. PMC: 90088. DOI: 10.1128/AAC.44.9.2475-2484.2000. View

15.

Bowes J, Brown A, Hamon J, Jarolimek W, Sridhar A, Waldron G . Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012; 11(12):909-22. DOI: 10.1038/nrd3845. View

16.

Moore R, Chaisson R . Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999; 13(14):1933-42. DOI: 10.1097/00002030-199910010-00017. View

17.

Adamson C, Freed E . Novel approaches to inhibiting HIV-1 replication. Antiviral Res. 2009; 85(1):119-41. PMC: 2815006. DOI: 10.1016/j.antiviral.2009.09.009. View

18.

Lee W, Gallardo-Macias R, Frey K, Spasov K, Bollini M, Anderson K . Picomolar inhibitors of HIV reverse transcriptase featuring bicyclic replacement of a cyanovinylphenyl group. J Am Chem Soc. 2013; 135(44):16705-13. PMC: 3877923. DOI: 10.1021/ja408917n. View

19.

Chan A, Lee W, Spasov K, Cisneros J, Kudalkar S, Petrova Z . Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography. Proc Natl Acad Sci U S A. 2017; 114(36):9725-9730. PMC: 5594698. DOI: 10.1073/pnas.1711463114. View

20.

Wei X, Ghosh S, Taylor M, Johnson V, Emini E, Deutsch P . Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995; 373(6510):117-22. DOI: 10.1038/373117a0. View